258
Participants
Start Date
June 30, 2008
Primary Completion Date
December 31, 2012
Study Completion Date
February 28, 2013
Etanercept
Commercially available etanercept administered subcutaneously at 50 mg/week.
Methotrexate
Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
Research Site, Vancouver
Research Site, Victoria
Research Site, Victoria
Research Site, Winnipeg
Research Site, Quispamsis
Research Site, St. John's
Research Site, St. John's
Research Site, Sydney
Research Site, Bowmanville
Research Site, Brampton
Research Site, Burlington
Research Site, Hamilton
Research Site, London
Research Site, Mississauga
Research Site, Newmarket
Research Site, Ottawa
Research Site, St. Catharines
Research Site, Toronto
Research Site, Toronto
Research Site, Laval
Research Site, Montreal
Research Site, Montreal
Research Site, Montreal
Research Site, Québec
Research Site, Rimouski
Research Site, Saint-Eustache
Research Site, Saint-Léonard
Research Site, Saskatoon
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Amgen
INDUSTRY